Please login to the form below

Not currently logged in
Email:
Password:

Zortress

This page shows the latest Zortress news and features for those working in and with pharma, biotech and healthcare.

Jobs to do

Jobs to do

having the potential for the management of Alzheimer's disease, or everolimus (Afinitor/ Zortress, originally developed for organ transplantation) in multiple types of cancer tumour.

Latest news

  • Novartis' Zortress cleared by FDA for liver transplants Novartis' Zortress cleared by FDA for liver transplants

    Novartis' Zortress cleared by FDA for liver transplants. Adds to kidney transplant indication in the US. ... Zortress/Certican achieved sales of $210m in transplantation, a rise of 20 per cent.

  • Antares hires Jonathan Jaffe as VP clinical development

    Antares hires Jonathan Jaffe as VP clinical development. His research experience includes time spent working on Novartis’ Zortress and Xolair. ... Drugs that Dr Jaffe has worked on during his time as a researcher include Novartis' Zortress (everolimus)

  • FDA approves Afinitor for pancreatic cancer

    In the US, everolimus is also available in different dosage strengths under the trade name Zortress for the prophylaxis of organ rejection in adult patients at low-moderate immunologic risk receiving

  • FDA clears test for Novartis' Zortress

    FDA clears test for Novartis' Zortress. The US Food and Drug Administration has cleared a test that monitors blood levels of Novartis' recently approved immunosuppressant Zortress. ... The US Food and Drug Administration (FDA) has cleared a test that

  • Getting the GIST

    Several mTOR antagonists have already been launched for different cancers and could therefore be prescribed as off-label therapy; these include everolimus (Zortress/Certican, Novartis), sirolimus (Rapamune, Wyeth) and temsirolimus (Torisel,

More from news
Approximately 1 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Infographics